Initially, 25 mg once a day. Maintenance dose: 25 to 50 mg once a day with main meal. When lesions have resolved sufficiently, terminate therapy.|
Dry mouth, runny nose, dry eyes, cracking of the lips, nosebleeds, skin peeling, hair loss, dry skin and lips, nail disorder, itching, rash, increased sensitivity to touch, inflammation of fingers or toes, sticky skin, joint pain, muscle pain, abnormal spinal bone growth, severe headache, abnormal liver function, lipid elevation, rigidity, Depression, Insomnia|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).